Learn how Prolaris could change your patients’ prostate cancer treatment plan.
For years, prostate cancer risk has been measured by PSA, Gleason and stage. However, traditional assessment no longer provides all the information needed to accurately predict prostate cancer risk. The Prolaris score combined with clinical and pathologic factors, estimates a patients’ 10-year prostate cancer mortality risk and a 10-year risk of developing metastatic disease.
“Living with Prostate Cancer is Possible”
Prostate cancer CCP gene expression levels vary widely, averaging more towards slow growing, indolent disease compared to other common cancers that are often more aggressive. Stratification can lead to more personalized treatment decisions that could help minimize over and under-treatment of localized prostate cancer. Prolaris can provide a new level of confidence when choosing active surveillance as a cancer treatment plan.
“Let’s look at other options before we do anything.”
Three steps closer to improving your post-diagnosis lifestyle
The patients’ prostate tissue sample will be sent to Myriad where it will be tested and analyzed to determine the aggressiveness of their prostate cancer.
The tissue sample is then shaved into thin sections and attached to slides which are then dyed and processed. Any remaining tissue is sent back to the pathology lab.
Once the sample(s) have been processed the results are sent directly to your practice. The results will contain the patients’ personalized Prolaris Score as well as their 10-year prostate cancer mortality risk.
Follow these steps when ordering tests for patients.
Myriad, the Myriad logo, Prolaris, Prolaris Score and the Prolaris logo are either trademarks or registered trademarks of Myriad Genetics, Inc., in the United States and other jurisdictions.
©2018 Myriad Genetic Laboratories, Inc.